$15.25
2.74% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US62855J1043
Symbol
MYGN

Myriad Genetics, Inc. Stock price

$15.25
-8.73 36.41% 1M
-9.41 38.16% 6M
-3.89 20.32% YTD
-2.17 12.46% 1Y
-14.34 48.46% 3Y
-9.49 38.36% 5Y
-17.40 53.29% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.43 2.74%
ISIN
US62855J1043
Symbol
MYGN
Sector
Industry

Key metrics

Market capitalization $1.39b
Enterprise Value $1.43b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.74
P/S ratio (TTM) P/S ratio 1.69
P/B ratio (TTM) P/B ratio 1.90
Revenue growth (TTM) Revenue growth 12.15%
Revenue (TTM) Revenue $823.60m
EBIT (operating result TTM) EBIT $-103.20m
Free Cash Flow (TTM) Free Cash Flow $-88.80m
Cash position $99.90m
EPS (TTM) EPS $-1.30
P/E forward negative
P/S forward 1.69
EV/Sales forward 1.75
Short interest 6.91%
Show more

Is Myriad Genetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Myriad Genetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Myriad Genetics, Inc. forecast:

7x Buy
44%
5x Hold
31%
4x Sell
25%

Analyst Opinions

16 Analysts have issued a Myriad Genetics, Inc. forecast:

Buy
44%
Hold
31%
Sell
25%

Financial data from Myriad Genetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
824 824
12% 12%
100%
- Direct Costs 297 297
10% 10%
36%
527 527
14% 14%
64%
- Selling and Administrative Expenses 467 467
3% 3%
57%
- Research and Development Expense 102 102
11% 11%
12%
-42 -42
50% 50%
-5%
- Depreciation and Amortization 61 61
15% 15%
7%
EBIT (Operating Income) EBIT -103 -103
34% 34%
-13%
Net Profit -116 -116
58% 58%
-14%

In millions USD.

Don't miss a Thing! We will send you all news about Myriad Genetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Myriad Genetics, Inc. Stock News

Neutral
Seeking Alpha
6 days ago
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Matt Scalo - Senior Vice President of Investor Relations Paul Diaz - President and Chief Executive Officer Scott Leffler - Chief Financial Officer Sam Raha - Chief Operating Officer Mark Verratti - Chief Commercial Officer Conference Call Participants Douglas Schenkel - Wolfe R...
Neutral
GlobeNewsWire
8 days ago
Highlights Third quarter revenue grew 11% year-over-year to $213 million , driven by Pharmacogenomics ( 34% ) and Prenatal ( 10% ) and progress on payor coverage and revenue cycle initiatives. Third quarter GAAP net loss improved to $22.1 million from a loss of $61.3 million in the third quarter of 2023 on improved revenue, gross margins and disciplined management of operating expenses.
Neutral
GlobeNewsWire
12 days ago
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effec...
More Myriad Genetics, Inc. News

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Paul Diaz
Employees 2,700
Founded 1991
Website www.myriad.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today